AstraZeneca shares drop on lung cancer trial update

AstraZeneca

The share price of AstraZeneca took a big hit on Tuesday after investors reacted to disappointing news from the company's latest lung cancer trials.

AstraZeneca

10 September 2024 11:52:20

Source: Sharecast

According to a company presentation at the IASLC 2024 World Conference on Lung Cancer in San Diego, overall survival rates "did not reach statistical significance" in the TROPION-Lung01 trial, which evaluated AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy.

Datopotamab deruxtecan (otherwise known as Dato-DXd) was being evaluated against docetaxel, the current standard of care chemotherapy, in adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy.

Nevertheless, detailed results from the phase III trial still showed a "clinically meaningful trend toward improving overall survival" with Dato-DXd compared to docetaxel, AstraZeneca said.

"Together with the data we have presented for the potential TROP2-QCS biomarker and from NeoCOAST-2 in early-stage disease, these results underscore our confidence in the important role datopotamab deruxtecan can play across segments and settings of non-small cell lung cancer," said Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca.

The stock was down 4.2% at 12,182p by 1149 BST, having fallen as much as 5.6% earlier on.

Exchange: London Stock Exchange
Sell:
0.00
Buy:
0.00
Change:
2.09
(0.02%)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

IWeb is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.